TP53 and ovarian endometrioid adenocarcinoma: 96% of high-grade serous ovarian cancer cases have p53 mutations, while clear cell ovarian cancer and endometrioid ovarian cancer usually do not carry TP53 mutations.84, 85, 86 p53 plays an important role in the development of ovarian cancer and its immunotherapy.